近年来亦在多项科研计划中担任主持人或是共同主持人。 Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer Han-Sheng Changa,1, Tzu-Chun Chengb,1, Shih-Hsin Tuc,d,1, Chih-Hsiung Wuc...
[4]Nuciforo P , Townend J , Piccart M J ,et al.Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer[J].European journal of cancer: official journal for European Organization ...
HER2-positive breast cancer has a distinctive biology, wherein amplification of the HER2 oncogene leads to a cascade of downstream effects. While in the past this distinctive biology was associated with a higher risk of recurrence and impaired long-term outcome, our current understanding of this ...
参考文献：[1]Petit T, Hajjaji N, Antoine EC, et al. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France. Cancer Med. 2024 May;13(9):e7168.审批编号：CN-148870 有效期至：2025...
[8] Salgado RF, Bardia A, Curigliano G,et al. HER2-low and HER2-ultralow status determination in tumors of patients with hormone receptor–positive metastatic breast cancer in DESTINY-Breast06. 2024 ESMO. LBA21. [9]Prat A, Modi S, Tsurutani JJ, et al. Determination of HER2-low status...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drug...
Hatem Soliman, MD, discusses the current first-line treatment options for patients with HER2-positive breast cancer.
Towards personalized treatment for early stage HER2-positive breast cancer Article 13 December 2019 Main The discovery of the human epidermal growth factor receptor 2 (HER2) (King et al, 1985; Schechter et al, 1985), its association with poor prognosis in breast cancer (Slamon et al, 1987...
HER2‐positive breast cancerT‐DM1trastuzumabtucatinibBackground Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)﹑ositive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous ...
[4]Lin N.U., Borges V., Anders C., et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–2619. ...